Last reviewed · How we verify
Transfersome
Transfersome is a Small molecule drug developed by Celtic Pharma Development Services. It is currently in Phase 3 development.
Transfersome is a proprietary drug delivery technology developed by IDEA AG, a German company, designed to exhibit characteristics of a cell vesicle for controlled and potentially targeted drug delivery. It has been studied in clinical trials for various conditions, including osteoarthritis, onychomycosis, and musculoskeletal pain, using ketoprofen as the active ingredient.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Transfersome |
|---|---|
| Sponsor | Celtic Pharma Development Services |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- TDT 067 Onychomycosis Study (PHASE3)
- Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise (PHASE1)
- Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA) (PHASE3)
- Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee (PHASE3)
- Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transfersome CI brief — competitive landscape report
- Transfersome updates RSS · CI watch RSS
- Celtic Pharma Development Services portfolio CI
Frequently asked questions about Transfersome
What is Transfersome?
Who makes Transfersome?
What development phase is Transfersome in?
Related
- Manufacturer: Celtic Pharma Development Services — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing